1μg (R: reducing condition).
CD27 Fc Chimera Protein, Mouse
CD27 Fc Chimera Protein, Mouse
Price:
Regular price
$240 USD
Regular price
Sale price
$240 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Species | Mouse |
| Synonyms | TNFRSF7, T14, S152, Tp55, Cluster of differentiation 27 |
| Accession | P41272 |
| Amino Acid Sequence | Thr21-Arg182 with Human IgG1 Fc at the C-Terminus |
| Expression System | HEK293 |
| Molecular Weight | 50-70kDa (Reducing) |
| Purity | >95% by SDS-PAGE, RP-HPLC&SEC-HPLC |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | Human IgG1 Fc |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, pH7.4, 5% trehalose |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage |
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference |
|
Background
Cluster of Differentiation 27 (CD27) is a member of the Tumor Necrosis Factor Receptor superfamily and is integral to T-cell activation, providing a crucial costimulatory signal. When CD27 binds to its natural ligand, CD70, it enhances T-cell proliferation and the differentiation of effector and memory T cells. This interaction holds potential as an immune modulatory target for cancer treatment.
The CD27 agonistic antibody, varlilumab, has demonstrated promising efficacy in both hematological malignancies and solid tumors. Current research is focused on studying the combination therapy of varlilumab with PD-1 axis inhibitors, such as nivolumab or atezolizumab, which target immune checkpoint pathways.
Furthermore, CD70 expression is being explored as a therapeutic target for Antibody-Drug Conjugates (ADCs), antibodies that induce Antibody-Dependent Cellular Cytotoxicity (ADCC), as well as for chimeric antigen receptor (CAR) gene-modified T cells and specific dendritic cell vaccinations.
Clinical trials have shown that targeting the CD27 axis is feasible and safe, with the most common side effects being thrombocytopenia, fatigue, and nausea.
Picture
Picture
SDS-PAGE
SEC-HPLC
The purity of CD27 Fc Chimera Protein, Mouse is more than 95% determined by SEC-HPLC.
RP-HPLC
The purity of CD27 Fc Chimera Protein, Mouse is more than 95% determined by RP-HPLC.
ELISA
Immobilized CD27 Fc Chimera Protein, Mouse (Cat. No. UA011079) at 5.0μg/mL (100μL/well) can bind CD27 LigandTNFSF7 His Tag, Mouse with EC50 of 27.86-39.99ng/mL.
Immobilized CD27 Fc Chimera Protein, Mouse (Cat. No. UA011079) at 2.0μg/mL (100μL/well) can bind Biotinylated CD27 Ligand/TNFSF7 Fc Chimera Protein, Human with EC50 of 5.99-8.93 ng/mL.
